Fatigue is a reliable, sensitive and unique outcome measure in rheumatoid arthritis.
AffiliationRheumatology Rehabilitation, Our Lady's Hospice, Harold's Cross, Dublin 6, Ireland. email@example.com
Tumor Necrosis Factor-alpha
MetadataShow full item record
CitationFatigue is a reliable, sensitive and unique outcome measure in rheumatoid arthritis. 2009, 48 (12):1533-6 Rheumatology (Oxford)
JournalRheumatology (Oxford, England)
AbstractFatigue is an important symptom in patients with RA. Measurement of fatigue in clinical trials and in clinical practice requires scales that are reproducible, sensitive to change and practical. This study examined the reliability and sensitivity to change of fatigue and its relative independence as an outcome measure in RA.
Successive patients referred to the rheumatology clinic at St Vincent's University Hospital and Our Lady's Hospice were evaluated. Clinical assessments were undertaken at baseline and 3 months after commencing TNF-alpha blockade. Fatigue was measured using an 11-point numeric rating scale (NRS). Sensitivity to change when compared with current core set outcome measures was determined by calculation of the standardized response mean (SRM). Multiple regression analysis was employed to determine the independent variance of fatigue scores relative to the core set.
Forty-nine patients were evaluated. At baseline, mean (s.d.) fatigue scores were 6.7 +/- 2.1. At 3 months, fatigue scores had fallen to 4.3 +/- 2.6 (P < 0.001). Test-retest intraclass correlation coefficient for the NRS was 0.79 (P < 0.008). Fatigue was ranked third for relative sensitivity to change as shown by SRM: pain, 1.37; tender joint count (TJC), 1.09; fatigue, 0.92; swollen joint count (SJC), 0.86; HAQ, 0.82; CRP, 0.69; and patient global health (GH), 0.25. The relative independent variance in fatigue of 22% was higher than that of the core set: TJC, 20%; pain, 19%; SJC, 16%; GH, 8%; HAQ, 7%; and CRP, 8%.
This study demonstrates that measures of fatigue are reliable and sensitive to change, and should be considered for inclusion as a core outcome measure in RA.
- Short-term outcome after anti-tumor necrosis factor-alpha therapy in rheumatoid arthritis: do we need to revise our assessment criteria?
- Authors: El Miedany Y, Youssef SS, El Gaafary M
- Issue date: 2006 Mar
- Fatigue is an independent outcome measure and is sensitive to change in patients with psoriatic arthritis.
- Authors: Minnock P, Kirwan J, Veale D, Fitzgerald O, Bresnihan B
- Issue date: 2010 May-Jun
- Evaluation and documentation of rheumatoid arthritis disease status in the clinic: which variables best predict change in therapy.
- Authors: Wolfe F, Pincus T, O'Dell J
- Issue date: 2001 Jul
- Fatigue, rheumatoid arthritis, and anti-tumor necrosis factor therapy: an investigation in 24,831 patients.
- Authors: Wolfe F, Michaud K
- Issue date: 2004 Nov
- Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group.
- Authors: Tugwell P, Wells G, Strand V, Maetzel A, Bombardier C, Crawford B, Dorrier C, Thompson A
- Issue date: 2000 Mar